Cargando…
Species Differences in Stereoselective Pharmacokinetics of HSG4112, A New Anti-Obesity Agent
HSG4112, a racemic drug, is a new anti-obesity agent. In this study, the stereoselective pharmacokinetics of HSG4112 were investigated in rats and dogs, and the underlying mechanism was investigated. The plasma concentrations of HSG4112(S) and HSG4112(R) were quantitated in plasma from rats and beag...
Autores principales: | Bae, In Yong, Choi, Min Sun, Ji, Young Seok, Yoo, Sang-Ku, Kim, Kyungil, Yoo, Hye Hyun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076457/ https://www.ncbi.nlm.nih.gov/pubmed/32028738 http://dx.doi.org/10.3390/pharmaceutics12020127 |
Ejemplares similares
-
Discovery and preclinical efficacy of HSG4112, a synthetic structural analog of glabridin, for the treatment of obesity
por: Choi, Leo Sungwong, et al.
Publicado: (2020) -
Effect of anti-obesity agent HSG4112 on overweight and obese patients following 12 weeks of oral treatment: a study protocol for a randomised, double-blind, placebo-controlled, parallel-group, phase 2a clinical trial
por: Min, Kyungha, et al.
Publicado: (2023) -
Hysterosalpingographic (HSG) Pattern of Infertility in Women of Reproductive Age
por: Onwuchekwa, Chinwe R., et al.
Publicado: (2017) -
Pro-apoptotic effects of rHSG on C6 glioma cells
por: Gao, Peng, et al.
Publicado: (2016) -
The Relations Between HSG Proven Tubal Occlusion, Stimulated Intrauterine Insemination and Pregnancy Rate
por: Yetkin Yıldırım, Gonca, et al.
Publicado: (2017)